Stanford Medicine

Running trials

• Not yet recruiting

  Rethinking Early Airway Clearence Therapies

  NCT07696338· Source

• Recruiting

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

  NCT07444476· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

  NCT07517133· Phase 3· Source

• Recruiting

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07589634· Phase 2· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Active, not recruiting

  GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

  NCT07228117· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  NCT07213791· Phase 1· Source

• Recruiting

  AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  NCT06959524· Source

• Recruiting

  A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  NCT07114601· Phase 1· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Source

• Recruiting

  Rapid Evacuation and Access of Cerebral Hemorrhage Trial

  NCT06870812· Source

• Active, not recruiting

  Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

  NCT06814145· Phase 2· Source

• Recruiting

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· Phase 1/2· Source

• Recruiting

  A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  NCT06925542· Phase 1· Source

• Recruiting

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· Phase 2/3· Source

• Recruiting

  StrokeNet Thrombectomy Endovascular Platform

  NCT06289985· Source

• Recruiting

  A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  NCT06706076· Phase 1/2· Source

• Active, not recruiting

  Phase 2b Open-Label Repeat Kidney Biopsy Study

  NCT06740526· Phase 2· Source

• Active, not recruiting

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· Phase 2· Source

• Recruiting

  Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

  NCT06217302· Phase 3· Source

• Recruiting

  Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  NCT06562192· Phase 1· Source

• Recruiting

  Food Insecurity Reduction & Strategy Team

  NCT06329375· Source

• Active, not recruiting

  KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

  NCT06384976· Phase 2· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Source

• Recruiting

  KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

  NCT06193889· Phase 2/3· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Source

• Recruiting

  Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

  NCT06098430· Source

• Recruiting

  A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06153251· Phase 1· Source

• Active, not recruiting

  Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

  NCT06096337· Source

• Recruiting

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· Phase 3· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· Source

• Active, not recruiting

  XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

  NCT05881278· Source

• Recruiting

  A Registry for People With T-cell Lymphoma

  NCT05978141· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Source

• Active, not recruiting

  Colorectal Cancer Screening in Cystic Fibrosis

  NCT05362344· Source

• Active, not recruiting

  Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  NCT05069558· Source

• Recruiting

  A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  NCT05201781· Phase 4· Source

• Recruiting

  A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

  NCT05118789· Phase 1/2· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

  NCT04770753· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

  NCT04770779· Phase 3· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Source

• Enrolling by invitation

  Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

  NCT04930289· Source

• Active, not recruiting

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· Phase 3· Source

• Recruiting

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· Phase 1/2· Source

• Active, not recruiting

  A Study of AL102 in Patients With Progressing Desmoid Tumors

  NCT04871282· Phase 2/3· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers5 recruiting
• Cystic fibrosis4 recruiting
• Lung cancer4 recruiting
• Multiple myeloma4 recruiting
• Prostate cancer4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• High blood pressure3 recruiting
• Hodgkin lymphoma3 recruiting
• Pancreatic cancer3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Stroke3 recruiting
• Type 1 diabetes3 recruiting
• Acute myeloid leukemia2 recruiting
• Gastric and esophageal cancer2 recruiting
• Spinal muscular atrophy2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Fabry disease1 recruiting
• Follicular lymphoma1 recruiting
• Gaucher disease1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Pompe disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

  NCT06676072· Source

• Terminated

  KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

  NCT06400303· Phase 1/2· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Source

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Source

• Completed

  Pharmacological Enhancement of Glymphatic Function in Humans

  NCT07432997· Phase 1/2· Source

• Completed

  A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

  NCT06064929· Phase 1· Source

• Completed

  Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

  NCT05794139· Phase 2· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· Source

• Completed

  FAME II-10-year Follow-Up

  NCT06159231· Source

• Completed

  A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

  NCT05717686· Phase 1· Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Phase 1· Source

• Completed

  A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  NCT05347485· Phase 2· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Source

• Completed

  The PROMISE Pediatric Study 6 to 11 Years Old

  NCT04613128· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· Source

• Completed

  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

  NCT04729907· Phase 3· Source

• Terminated

  A Phase 1 Study of ADI-001 in B Cell Malignancies

  NCT04735471· Phase 1· Source

• Completed

  Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease

  NCT04547712· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Completed

  A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function

  NCT04038047· Source

• Completed

  A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

  NCT03978689· Phase 1· Source

• Terminated

  A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

  NCT03731637· Source

• Completed

  A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

  NCT03032172· Phase 2· Source

• Completed

  Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

  NCT02913482· Phase 2· Source

• Completed

  A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

  NCT02932449· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Source

• Completed

  Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

  NCT01868451· Source

Trial sites

• Stanford Medicine8 trials
• Stanford University Medical Center37 trials
• Stanford Medicine2 trials
• Stanford University Medical Center3 trials
• Stanford University Medical Center1 trial
• Stanford Medicine2 trials
• Stanford University Medical Center55 trials
• Stanford University Medical Center (Data collection only)2 trials
• Stanford University Medical Center - Neurology1 trial
• Stanford University Medical Center (Site 1024)1 trial
• Stanford University Medical Center- Site Number : 84001081 trial
• Stanford University Medical Center- Site Number : 8400211 trial
• Stanford University Medical Center- Site Number : 8400222 trials
• Stanford Univ Med Ctr1 trial
• Stanford Univ Medical Center1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease401 works · 2 trials
• Lung cancer380 works · 6 trials
• Stroke260 works · 8 trials
• Heart failure236 works · 3 trials
• Prostate cancer185 works · 5 trials
• Obesity183 works · 0 trials
• Colorectal cancer157 works · 5 trials
• Parkinson disease144 works · 2 trials
• Glioblastoma138 works · 1 trials
• Type 2 diabetes105 works · 5 trials
• Ovarian cancer103 works · 1 trials
• Liver and biliary tract cancer100 works · 2 trials
• Atrial fibrillation100 works · 4 trials
• Melanoma99 works · 0 trials
• Acute myeloid leukemia94 works · 2 trials
• Gastric and esophageal cancer94 works · 3 trials
• Pancreatic cancer86 works · 3 trials
• Chronic kidney disease84 works · 2 trials
• Multiple sclerosis81 works · 4 trials
• Coronary artery disease79 works · 5 trials
• Type 1 diabetes73 works · 5 trials
• HIV68 works · 1 trials
• Epilepsy65 works · 0 trials
• Sarcoma57 works · 3 trials
• Bladder cancer57 works · 1 trials
• Fatty liver disease (MASLD/MASH)46 works · 1 trials
• Amyloidosis46 works · 0 trials
• Rheumatoid arthritis46 works · 1 trials
• Long COVID and ME/CFS46 works · 0 trials
• Tuberculosis45 works · 0 trials